Cagrilintide 5 mg

Cagrilintide is a synthetic long-acting peptide analog derived from the endogenous hormone amylin. It is primarily studied for its role in appetite regulation, energy balance, and metabolic signaling through activation of amylin and calcitonin receptor pathways. Unlike native amylin, which has a very short half-life, Cagrilintide is structurally modified to allow sustained biological activity.

Research interest in Cagrilintide focuses on its ability to influence satiety signaling, reduce food intake, modulate gastric emptying, and regulate glucose and lipid metabolism. Due to its dual receptor activity and prolonged half-life, it is widely investigated in experimental models related to obesity, metabolic regulation, and endocrine control of body weight.

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling.

Cagrilintide activates amylin receptors (AMY1, AMY2, AMY3) and calcitonin receptors in the hypothalamus and brainstem, suppressing appetite and slowing gastric emptying independently of the GLP-1 pathway. This complementary mechanism has driven research into its combination with semaglutide (CagriSema), which has shown additive weight reduction in clinical trials. The dual amylin/calcitonin receptor activation distinguishes cagrilintide from GLP-1-based compounds and offers a distinct research profile (Enebo et al., 2021 — Lancet).

The peptide is supplied as a lyophilized powder to ensure optimal stability during storage and handling. Store at -20°C. See also: Cagrilintide 10 mg, Semaglutide 10 mg, Tirzepatide 10 mg